Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

Laura Pizzuti, Domenico Sergi, Isabella Sperduti, Luigi Di Lauro, Marco Mazzotta, Claudio Botti, Fiorentino Izzo, Luca Marchetti, Silverio Tomao, Paolo Marchetti, Clara Natoli, Antonino Grassadonia, Teresa Gamucci, Lucia Mentuccia, Emanuela Magnolfi, Angela Vaccaro, Alessandra Cassano, Ernesto Rossi, Andrea Botticelli, Valentina SiniMaria G. Sarobba, Maria Agnese Fabbri, Luca Moscetti, Antonio Astone, Andrea Michelotti, Claudia De Angelis, Ilaria Bertolini, Francesco Angelini, Gennaro Ciliberto, Marcello Maugeri-Saccà, Antonio Giordano, Maddalena Barba, Patrizia Vici

Research output: Contribution to journalArticle

Abstract

The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger cohort previously assessed for treatment outcomes. Patients were included in the present analysis if body mass index values had been recorded at baseline. Clinical benefit rates, progression free survival and overall survival were assessed for the overall study population and subgroups defined upon molecular subtype. One hundred ninety six patients were included (N:196). Body mass index showed no impact on clinical benefit rates in the overall study sample and in the luminal cancer subset (p = 0.12 and p = 0.79, respectively), but did so in the triple negative subgroup, with higher rates in patients with body mass index ≥25 (p = 0.03). In the overall study sample, body mass index did no impact progression free or overall survival (p = 0.33 and p = 0.67, respectively). Conversely, in triple negative patients, progression free survival was significantly longer with body mass index ≥25 (6 vs 14 months, p = 0.04). In this subset, overall survival was more favorable (25 vs 19 months, p = 0.02). The impact of the molecular subtype was confirmed in multivariate models including the length of progression free survival, and number of metastatic sites (p < 0.0001). Further studies are warranted to confirm our findings in more adequately sized, ad hoc, prospective studies.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalCancer Biology and Therapy
DOIs
Publication statusAccepted/In press - Feb 9 2018

    Fingerprint

Keywords

  • Bevacizumab-including regimens
  • BMI
  • first-line treatment
  • HER2-negative metastatic breast cancer
  • triple negative subtype

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Pizzuti, L., Sergi, D., Sperduti, I., Lauro, L. D., Mazzotta, M., Botti, C., Izzo, F., Marchetti, L., Tomao, S., Marchetti, P., Natoli, C., Grassadonia, A., Gamucci, T., Mentuccia, L., Magnolfi, E., Vaccaro, A., Cassano, A., Rossi, E., Botticelli, A., ... Vici, P. (Accepted/In press). Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. Cancer Biology and Therapy, 1-7. https://doi.org/10.1080/15384047.2017.1416938